Investigational Seladelpar Shows Promise in Treating Liver Disease and Itching in Primary Biliary Cholangitis
Gilead Sciences, Inc. recently released interim results from the ongoing ASSURE study, revealing significant improvements in liver disease progression and reduced itching in patients with primary biliary cholangitis (PBC) who were treated with seladelpar, an investigational PPAR delta agonist. This promising development comes after Gilead acquired CymaBay Therapeutics, Inc. In addition to this, Gilead’s subsidiary, Kite, and its partner Arcellx, shared updates on their anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel, the first BCMA CAR T therapy being investigated in multiple myeloma using Arcellx’s innovative D-Domain binder, has shown significant progress and promises hope for patients.
Liver disease progression is a major concern for individuals living with PBC, a chronic and progressive autoimmune disease that affects the bile ducts in the liver, leading to inflammation, scarring, and impaired liver function. PBC can cause severe itching or pruritus, which significantly impacts patients’ quality of life. However, the recent findings from the ASSURE study provide hope for improved treatment options.
The interim results from the ASSURE study demonstrated that seladelpar led to improvements in markers of cholestasis, a condition characterized by the inability of the liver to properly transport bile, and reduced inflammation in PBC patients. Cholestasis is a primary feature of PBC and plays a role in the progression of the disease. By addressing this aspect, seladelpar shows potential in slowing down the progression of liver damage.
Furthermore, the study also showed that seladelpar helped reduce pruritus in PBC patients. Pruritus is a distressing symptom commonly experienced by individuals with liver diseases. Finding effective treatments that alleviate itching is crucial in improving patients’ overall well-being.
These positive findings provide optimism for the development of seladelpar as a potential therapeutic option for patients with PBC. However, it is important to note that further research and clinical trials are still needed to establish the drug’s safety and efficacy conclusively.
Additionally, Gilead’s subsidiary, Kite, and its partner Arcellx have made significant strides in the field of multiple myeloma treatment. Multiple myeloma is a cancer of plasma cells, a type of white blood cell primarily found in bone marrow. The partnership between Kite and Arcellx has resulted in the development of anitocabtagene autoleucel (anito-cel), a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA).
Anito-cel is the first BCMA CAR T therapy to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The binding affinity of D-Domain binder to BCMA is expected to enhance the therapy’s effectiveness in targeting cancer cells. The companies announced the design of a global Phase 3 randomized controlled clinical trial, iMMagine-3, showcasing their commitment to advancing anito-cel as a potential treatment for multiple myeloma.
The updates provided by Kite and Arcellx highlight the progress being made in the field of CAR T-cell therapy and the potential it holds for patients with multiple myeloma. The development of anito-cel and the initiation of the iMMagine-3 trial signify a step forward in providing hope and improved outcomes for individuals affected by this challenging disease.
In conclusion, the interim results from the ASSURE study on seladelpar demonstrate significant improvements in liver disease progression and reduced itching in patients with PBC. This brings hope for improved treatment options for individuals living with this chronic liver condition. Simultaneously, Kite and Arcellx’s anito-cel multiple myeloma program shows promise in advancing CAR T-cell therapy for patients with this form of cancer. These developments in liver disease and multiple myeloma treatment provide optimism for future advancements in these fields.
Comments